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Abstract
Carcinogenesis is the transformation of a normal cell into a cancerous cell. Cancer
chemoprevention is the use of natural and synthetic compounds to stop carcinogenesis. These
compounds have been labeled chemopreventives and they take advantage of the human body’s
natural defenses to stop carcinogenesis. Chalcones have demonstrated antibacterial, antifungal,
antitumor, and anti-inflammatory properties. In this project, chalcones and their derivatives are
synthesized with the goal to be used as possible chemopreventives. We believe that when tested
on cancer cell lines, the boronic acid derivative will show greater chemopreventive activity
because of the boronic acid’s increased bioavailability. We have synthesized and characterized a
series of methoxy and boronic acid chalcones via adol condensation. Our synthetic methodology
included the conversion of hydroxybenzaldehydes into alkoxybenzaldehydes via Williamson
Ether Synthesis, followed by a Clasien-Schmidt condensation between the alkoxybenzaldehydes
and an acetophenone. The synthesized chalcones were characterized 1 H, 13 C, and 2D NMR
spectroscopy and were shown to exhibit yields ranging from 58% to 91%.
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CHAPTER 1
Introduction
Cancer can best be described as the disease of mayhem. This disease goes against the
natural order in which normal cells operate. Cancer typically attacks the organs in the human
body, by causing the uncontrollable growth of transformed cells. During this process, the human
genome acquires mutant alleles of proto-oncogenes, tumor suppressors and other genes that can
regulate cell proliferation. This accumulation of a transformed cell form a tumor which can be
either be benign (localized/noninvasive) or malignant (metastatic/invasive). In the majority of
cases it is the malignant tumors that are responsible for the largest part of deaths from cancer.
This disease is a complicated, multi step process that takes years to develop in humans, and can
involve a number of genes. Combinations of mutated-genes bring about the process of
carcinogenesis and studies have shown that a single gene mutation is not enough to start the
process of cancer. Carcinogenesis, the transformation of a normal cell to a cancer cell, can be
influenced by a person’s genetic makeup or by environmental factors.
Cancer has become a growing health epidemic plaguing the United States. It is estimated
that there is about 1.5 million new cancer cases in the United States and approximately five
hundred thousand deaths from cancer (Yadav, Prasad, Sung, & Aggarwal, 2011). Although
cancer is a worldwide problem, the number of cancer incidence rates, the rates with which the
disease is diagnosed, varies from country to country as well as regions to regions. According to
the International Agency for Research on Cancer, African Americans, in the United States of
America have the highest incidence rate of prostate cancer compared to any race in the world.
Regionally cancer varies dramatically (Weinberg, 2007). For instance, African Americans in
Louisiana have a higher incidence of lung cancer while Korean Americans in Los Angeles
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experience a higher incidence of pancreas cancer. In any case, cancer is an occurring issue across
the world.
1.1 Formation of Cancer
All cancers have a genetic basis. The accumulation of mutations in DNA is what brings
about the formation of cancer. The blue print of DNA is genes, whose main responsibility is to
keep cells in balanced. There are two known categories of genes that are associated with cancer,
proto-oncogenes and tumor suppressor genes. The elimination or transformation of these two
genes can result in the formation of cancer. Proto-oncogenes code for proteins that help with cell
growth and differentiation. As a result of DNA damage, these normal cellular genes become
inactivated and transform themselves into oncogenes. Oncogenes promote cell growth and are
expressed in high level in tumor cells. Tumor suppressor genes are genes that protect the cells
from advancing down the path towards cancer. Inactivation of these genes causes cell
proliferation (cell growth). The formation of cancer has been found to be the cause of oncogenes
rather than the tumor suppressor genes. This is because in order for the oncogene to be activated
it only takes one mutation, whereas tumor suppressor genes require multiple hits to become
activated (Weinberg, 2007).
The risk of developing cancer can be attributed to random mutations, inherited mutations,
viral infections and or environmental factors (Weinberg, 2007). Inherited mutations are predispositions that cause an abnormal gene that is passed from generation to generation. A
common misconception about inherited mutations is that a person will have cancer. In actuality,
persons with inherited mutations only inherit an abnormal gene that has the potential to bring
about cancer. There is still a possibility of that person never developing cancer.
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The known or suspected causes of human cancers can vary from region to region and is
based on a person environment or life style choices. Environmental factors are the leading causes
in the formation of cancer. A person is exposed to many carcinogens on a daily basis. Studies
have determined that only 5-10 % of cancer is caused by inheritance of mutated genes while 9095% of cancer has been linked to lifestyles and environmental factors (Yadav et al., 2011).
Infectious agents can lead to the transformation of a host cell, but is a preventable cause of
cancer (Carrillo-Infante, Abbadessa, Bagella, & Giordano, 2007). To combat a person’s constant
exposure to carcinogens developing a therapeutic that can prevent carcinogenesis would be
highly beneficial.
1.2 Cancer Cell Characteristics
Every cell goes through the cell cycle. The cell cycle for eukaryotes is divided into two
major periods: interphase, the process in which the cell grows, and mitosis, the phase where cell
division occurs. The duration of the cell cycle of a cancerous cell is sometimes faster or
prolonged than that of a normal cell (Diaz-Moralli, Tarrado-Castellarnau, Miranda, & Cascante,
2013). Within the cell cycle, check points are used to monitor and regulate the progression of a
cell. Check points are designed to ensure that damaged or incomplete DNA is not passed to a
daughter cell. The cell cycle utilizes certain enzymes, such as tumor suppressors, to inhibit the
cell cycle if a cell becomes cancerous.
Cancer cells exhibit behaviors found in a normal cell during development, differentiation
and homeostasis, but do not show normal regulatory control over these functions. There are
certain distinct properties of cancer cells that differentiate themselves from normal cells. Most
normal cells have a limited potential to divide, where as cancer cells show no limitations towards
divisions. Cancer cells do not undergo contact inhibition. They are invasive by creating new
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network of blood sources (angiogenesis) and most importantly they do not undergo apoptosis
naturally. Cancer cells are also known to metabolize glucose through glycolsis without the
formation of ATP and have a high pH levels within the cell. Given that cancer requires an acidic
and low oxygen environment to flourish, cancer patients have a very high blood pH of 6.5- 7.0 or
lower. Another factor that is common in all cancers is inflammation. Inflammation is a biological
response to harmful stimuli, and is classified into two stages; acute and chronic. Chronic
inflammation is known to be associated with most chronic illnesses, including diabetes, obesity
and cancer. Studies have shown that chronic inflammation is mandatory for the induction of an
immunosuppressive environment, due to the high concentrations of oxygen (Mikirova, Casciari,
Rogers, & Taylor, 2012).
1.3 Cancer Treatments
Treatments for cancer are prescribed based on a variety of factors that are specific to the
patients’ individual circumstances ("Overview: Cancer Treatments - Cancer," 2012). These
factors include the cancer stage, patients’ age, medical history and overall health. Each form of
cancer is different and requires different treatment approaches. However, the most common
approaches are radiation and chemotherapy. Both forms of therapy have the potential of
damaging both cancer cells and healthy cells. There are also newer forms of treatments emerging
on the frontier of cancer treatments and are in clinical trials.
Both surgical oncology and radiation therapy is used to treat localized cancer in the body.
Both forms are focused on the management of cancer. Surgery physically removes a tumor or is
sometimes used as a prevention measure. Radiation therapy is a method of treating cancer using
high-energy waves with the goal to kill cancer cells or limit their ability to grow and divide.
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Chemotherapy utilizes combinations of drugs that are either administered orally or
intravenously. Chemotherapy drugs target cells in the body that divide and grow at a rapid rate
("Overview: Cancer Treatments - Cancer," 2012). This form of treatment is commonly
prescribed to patients’ whose cancer is not localized. Chemotherapy can be used to reduce
symptoms as well as the pain associated with cancer. The duration of treatment is dependent on
the type of cancer, the area and a person’s individual response from their body to the drugs.
Chemotherapy drugs can be divided into several groups based on the following factors of
how they work, their chemical structures, and their relationship to another drug ("What are the
different types of chemotherapy drugs?," 2012). Alkylating agents work in all phases of the cell
cycle. Temodar® is an alkylating agents used to damage DNA and prevent cancer cells from
reproducing. Antimetabolites interfere with DNA and RNA growth during the S phase. Some
examples of antimetabolites are 5-fluorouracil, 6-mercaptopurine, Xeloda®, Hydroxyurea, and
Methotrexate. Mitotic inhibitors are plant alkaloids and other compounds derived from natural
products. Taxol® is an example of a mitotic inhibitor that stops mitosis or inhibit enzymes from
making proteins needed for cell reproduction.
Doctors also rely on clinical drugs and studies as an option to treat cancer patients.
Clinical trials are studies that utilize volunteers to take part in test of new drugs or procedures.
Amongst these new classes of drugs and procedures are electrochemotherapy and
chemopreventives. Electrochemotherapy combines injection of a chemotherapeutic drug
followed by the application of high-voltage electric pulses to the tumor site (Heller, Gilbert, &
Jaroszeski, 1999). Chemopreventive agents interfere with a disease process by halting
carcinogenesis.
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CHAPTER 2
Literature Review
2.1 Flavonoids
Phytohemicals are chemical compounds made by plants to help protect cells against
oxidative damage. Flavonoids are a group of compounds found in plants and serve as defense
mechanisms against herbivores and provide the intense pigments in flowers, fruits and leaves
(Dyrager, 2012).This group of compounds is made up of a structural class known as
polyphenols. Polyphenols are unique for the reason that they can be found within nature, but can
be synthesized. Flavonoids are recognized for their antioxidant properties, and are referred to as
“natures’ biological response” because of their ability to modify the body’s reaction to allergens
and viruses.
Dietary agents from fruits, vegetables, and spices are beginning to draw attention from
both the public and medical community because of their ability to suppress a variety of diseases
(Yadav et al., 2011). There is a variety of flavonoids and each kind is divided into classes based
off their molecular structures. The most common flavonoids found in the human diet are
flavones, flavonols, isoflavones, and neoflavones (Figure 1). Flavonoids are made up of three
heterocyclic rings, A, B & C. The common component within all the flavonoids is the ketone
functional group located in the C ring. This is believed to give the compound its activity as well
as its dynamic color, yellow. Given that flavonoids are distributed in the human diet they are
believed to be non-toxic compounds (Dyrager, 2012). Because they naturally occur and are
easily synthesized, they are appealing drug candidates, and can be classified as a
chemopreventive.
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Figure 1. Common flavonoids.
2.2 Chalcones
Chalcones (Figure 2) are the major intermediates in the biosynthesis of flavonoids. These
compounds and their derivatives can either be isolated from natural products or synthesized
using classic synthetic chemistry. Chalcones are being considered as anticancer agents because
they demonstrate variety of properties such as, antibacterial, antitumor and anti-inflammatory.
Chemically, they consist of two aromatic rings joined by a three carbon α, β- unsaturated
carbonyl system.
O

β

6
5

3'

α

A
4

2'

2

B
6'

3

4'
5'

Figure 2. General structure and numbering of a chalcone.
2.2.1 Synthesis of chalcones. Chalcones can be derived both naturally and synthetically.
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2.2.1.1 Natural biosynthesis of chalcones. Chalcones participate in the biosynthetic
pathways of flavonoids. Naturally, they are produced as a plant’s secondary metabolism
mechanism to aid in the growth and development of a plant. Secondary metabolisms play a key
role in keeping all of the plants’ system working properly by severing as defense mechanisms. In
a stepwise addition of L-phenylalanine, an amino acid, as the starting compound for the
flavonoid skeleton is formed (Scheme 1). In this reaction ammonia is removed to form a transcinnamate that is converted to a p-coumarate. The p-coumarate then undergoes ligation with
CoA-SH to form 4-coumaroyl-CoA (Yadav et al., 2011). From there 4-coumaroyl-CoA can go
through a naringenin-chalcone synthase and form a naringenin-chalcone. This chalcone can be
extracted from an apple tree leaf.
+
H2 NH3
C C COOH

COO-

trans-cinnamate 4mono oxygenase

COO-

Phenylalanine
Ammonia-lyase

HO
p-coumarate
trans-cinnamate

L-phenylalanin

4-coumarate
CoA ligase

O

O

O
Naringenin-chalcone
synthase

CoA-S

HO

O

CoA-S
HO

O

4-coumaroyl-CoA

CoA-SH
OH

HO

O

OH

OH

Naringenin chalcone

Scheme 1. Natural synthesis of chalcones.
2.2.1.2 Synthetic biosynthesis of chalcones. Synthetic chalcones are less complicated to
form than a naturally occurring chalcone. The key to forming a chalcone is the formation of the
enone functional group. An aldol condensation is an organic reaction involving an enol reacting
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with a carbonyl compound to form a β-hydroxyketone, followed by a dehydration to give a
conjugated enone. The more common way to form a chalcone is the Clasien-Schmidt
condensation. This reaction is an aldol condensation between a benzaldehyde and an
acetophenone in the presents of a base in a polar solvent (Scheme 2).
O

O
CH3

+

O

base
H

Scheme 2. Claisen-Schmidt condensation of a chalcone.
Recently different reactions have been used to form chalcones (Scheme 3). Scheme 3,
reaction I is the Suzuki coupling between cinnamoyl chloride and phenylboronic acid has been
reported but formed chalcones in yields ranging from 68%- 93% (Eddarir, Cotelle, Bakkour, &
Rolando, 2003). Another approach was the Heck coupling (Scheme 3, reaction II) with an aryl
halide with styrenes in the presence of carbon monoxide with yields ranging from 24%-65%
(Reichwald, Shimony, Sacerdoti-Sierra, Jaffe, & Kunick, 2008). Between both these reactions
the more promising yields came from the Suzuki coupling.

I.

OH
B
OH

Pd/base

+
Cl

Toluene
O

Pd/ligand

I

II.

+

+

CO

DMF

Scheme 3. Suzuki cross-coupling and Heck reaction formation of a chalcone.
2.2.2 Application of chalcones.

O
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2.2.2.1 Antibacterial. Chalcones have a broad spectrum of antibacterial activities, and
their diverse applications have become popular in the medical field. The equilibrium between the
open chalcone structures allows a variety of substitution on their rings which results in different
effects (Ávila, Smânia, Monache, & Smânia Júnior, 2008). Licochalcone is a chalcone obtained
from the glycyrrhiza glabra, a root in which licorice flavor comes from, has shown the ability
disrupt the cell membrane (Sivakumar et al., 2012). This is useful in the medical field where
they use chalcones to coat medical devices to prevent the colonization of bacteria.
2.2.2.2 Anti-inflammatory. Inflammation associated with cancer has been linked to the
excess production of nitric oxide, a free radical produced by the body. This nitric oxide has the
potential to destroy normal tissue during acute and chronic inflammation (Honda et al., 2000).
This is can also be correlated to the process of carcinogenesis (Honda et al., 2000).
Broussochalcone is a natural chalcone isolated from the Moraceae, a plant from the fig family.
This chalcone exerted potent antioxidant activity and inhibited the inducible nitric oxide synthase
(iNOS) expression in macrophages (Won et al., 2005). This inhibition of nitric oxide production
demonstrates how chalcones are potential anti-inflammatory and cancer chemopreventive drugs.
2.2.2.3 Antitumor. Invasion is the trademark of malignant tumors and usually leads to the
major cause of death in cancer patients (Mukherjee et al., 2001). If a cell is allowed to replicate
itself, its end result is the formation of a tumor. Chalcones contain an enone in its structure which
have been shown to reduce tubulin assembly (Johnson et al., 2007). Tubulins are composed of
microtubules which is a key component of the cytoskeleton of protein. Chalcones bind to the
tublin and prevent it from polymerizing into microtubules (Bandgar, Gawande, Bodade, Totre, &
Khobragade, 2010). When the cytoskeleton of a cell is destroyed it results in cell death. The
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obstruction of the microtubule system for the eukaryotic cells can be considered an important
target for the development of antitumor agents (Kong et al., 2010).
2.2.3 Chalcones as a chemopreventive. Carcinogenesis is a complex and a multistage
process in which a normal cell is transformed into a cancer cell. The human body is naturally
equipped with mechanisms to stop a transformed cell from continuing in the cell cycle by
utilizing the check points within the cycle and tumor suppressor genes. Chemopreventives are
synthetic drugs, whose structures are similar to compounds found in nature, and improve or
facilitate those processes the body uses to interrupt carcinogenesis. The goal as a
chemopreventive is to protect cells from carcinogens.
There are nine classes of chemopreventive drugs, (i) oxidizable diphenols and quinines,
(ii) Michael reations acceptors (olefins or acetylenes conjugated to electron withdrawing groups),
(iii) isothiocyanates, (iv) hydroperoxides, (v) trivalent arsenic derivatives, (vi) divalent heavy
metal cations (Hg2+ and Cd2+), (vii) vicinal dithiols, (vii) 1,2-dithiole-3-thiones, and (ix)
carotenoids and other conjugated polymers. These compounds induce phase II enzymes that
detoxify electrophiles and serve as an indirect antioxidant. Phase 2 drug-metabolizing enzymes,
glutathione S-transferases (GST) have the ability to conjugate Glutathione (GSH) and thereby
detoxify cellular environments (A. T. Dinkova-Kostova, Massiah, Bozak, Hicks, & Talalay,
2001). Glutathion is tripeptides produced naturally in humans, and with respect to cancer GSH
metabolism is ablet to play both protective and pathogenic roles (Balendiran, Dabur, & Fraser,
2004). Michael acceptors, cinnamates, chalcones, coumarins and curcuminods, have some type
of relationship between their conjugated benzylidene ketone structure that raises GSH levels in
cells (A. T. Dinkova-Kostova et al., 2001).
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Chalcones have been linked to inducing phase II enzymes (Albena T. Dinkova-Kostova,
Abeygunawardana, & Talalay, 1998). These enzymes provide protection against toxic chemical
species. Studies have shown that an elevation of phase II enzymes show a relationship with
protecting a cell against chemical-induced carcinogenesis (Bandgar et al., 2010). An approach
for protecting a cell is decreasing the metabolic enzymes response for generating reactive
species, while increasing phase II enzymes that can deactivate radicals (Bandgar et al., 2010).
For these reasons, cancer chemopreventives have become an attractive topic for the
pharmaceutical industry.
Other studies have also shown that chalcones have been effective in activating p53, a
tumor suppressor gene, resulting in apoptosis (Achanta, Modzelewska, Feng, Khan, & Huang,
2006). Many tumors are formed when tumor suppressor p53 becomes inactive, either by
mutation or by binding to oncoproteins. Oncoprotein MDM2 inhibits tumor suppressor protein
p53, by binding to its transactivation domain. When MDM2 is over expressed it disables a
genome checkpoint and allows the cell cycle to generate defective cells. Chalcones inhibit
MDM2 in which releases p53 (Stoll et al., 2001).
2.3 Boron
2.3.1 Origins. Boron is a non-metallic element, which can be found abundantly in nature
only when paired with sodium or carbon. Boron is required for normal growth and health of the
body, making it essential for life. American adults consume more boron than any other essential
trace elements such as copper or magnesium (Hunt, 2012). Small amount of boron compounds
play a strengthening role in cell walls of plants. This element is present in nuts, fresh fruits, green
vegetables as well as a main ingredient in multivitamins. Boron is also used in cosmetic products
as a preservative and pH adjuster ("Part 3 Trace Elements 3 164 General information Chemistry
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Boron is a," 2010). Boron containing compounds have found a common use in synthetic organic
chemistry in addition to applications in the biomedical field as a treatment for HIV, obesity,
diabetes and cancer (Cambre & Sumerlin, 2011).
2.3.2 Biological functions. Traces of boron can be located throughout the human body,
the main source being the consumption of plants in our diet. Boron is present in human plasma
(0.017-0.191 µg/mL) and in the liver (1.1-5.4 µg/g) (Hunt, 2012). In the human body, boron is
used to support biological functions such as inducing calcium and insulin metabolism as well as
bone growth. It is believed that boron improves the human body natural ability to absorb calcium
and magnesium. Diets depleted in boron have been shown to affect both the immune and nervous
systems (Cui et al., 2004). Many disease conditions, such as arthritis, osteoporosis, and
menopausal symptoms, are managed by boron. Boron is also known to alter human steroid
hormone levels, mainly testosterone and estrogen (Cui et al., 2004). Evidence from animal
experiments suggests that boron is essential during the rapid cell replication during the
fertilization cycles.
2.4 Boronic Acid
Boronic Acid is a Lewis acid belonging to the larger class of organoboranes (Figure 3).
This compound is stable and is easily handle which makes them an attractive class of synthetic
intermediates (Boronic Acids, 2005). Chemically, they consist of trivalent boron atom bonded to
one alkyl/aryl substituent and two hydroxyl groups, R-B(OH)2. Their empty p-orbital on Boron
allows the interconversion from sp2 to sp3 hybridization in the presences of a Lewis Base. These
compounds are unique and versatile which allows them to be used for the formation of C-C
bonds, asymmetric synthesis, molecular sensing, therapeutic agents and enzyme inhibitors
(Cambre & Sumerlin, 2011). Boronic acid is low in toxicity and degradation into

16
environmentally friendly boric acid allows it to be considered a “green” compound. There are a
variety of Boronic acids but arylboronic acids remain the most acknowledged class of boronic
acids.
II

R B
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R B

OH
RI

R B

OH
OH

R B

ORI
ORI

Boronic Ester
Borane

Borinic Acid

Boronic Acid
(RI = alkyl or aryl)

Figure 3. Oxygenated organoboron compounds.
2.4.1 Synthesis of boronic acid. Boronic acids are widely used in organic chemistry as
building blocks or intermediates. These compounds are not naturally occurring but are
commercially available. They can also be synthesized through several different methods. The
most familiar way is through organometallic compounds based on lithium or magnesium
grignard with a borate ester (Scheme 4, Reaction I). Another method is a transmetallation
reaction involving a trialkylsiyl derivative with a boron halide (Scheme 4, Reaction II). Boronic
acids are also popular cross-coupling intermediates in natural products synthesized in medicinal
chemistry. An example is the Suzuki-Miyaura cross-coupling reaction for synthesis of dienes and
other unsaturated units present in many natural products (Scheme 4, Reaction III). Presently, this
method is used in the pharmaceutical industry for the synthesis of PS-341, a new cancer therapy
in Phase I clinical evaluation for advanced cancer patients as an enzyme inhibitor (Yang, Gao, &
Wang, 2003).
2.4.2 Boronic acid as a chemopreventive. Boronic acid derivatives are of interest in
drug development because of their diverse characteristics towards cancers. These compounds are
known to have a role in the controlling of normal inflammatory response, as it relates to the
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production of various cell signaling (Hunt, 2012). The “potential mode of action” is through the
synthesis or activation of metabolites that regulate growth (Cui et al., 2004).
I.
R
X
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or HB(ORI)2
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H3O+
B(ORI)2
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Scheme 4. Common methods for the synthesis of arylboronic acids.
Boronic acid was also identified as a potential inhibitor of human cancer in cell
proliferation and angiogenesis (Kong et al., 2010). Other characteristic boronic acids have is
their ability to affect the cell pH level (Cambre & Sumerlin, 2011). When added on a phenyl
ring, it allows the pKa to be tuned so that boronic acid containing polymers can be employed in a
physiologically relevant pH range (Cambre & Sumerlin, 2011). It is the presence of the
hydroxyl groups that gives a compound its hydrophilicity (A. T. Dinkova-Kostova et al., 2001).
Cancer cells have a pH between 6.0-7.0, being very acidic, while Boronic acid derivatives have a
moderate pH of 9.0-10.0 and while maintaining air stability (Kong et al., 2010). Antibiotics
containing Boron inhibit DNA, RNA & protein synthesis and or disrupt membrane permeability.
There are several potential Boronic acid binding sites involved in prostate cancer (Cui et al.,
2004). The drug Bortezomib® is a compound containing a Boronic acid group which is used in
chemotherapy. This drug was the first proteasome inhibitor, a drug that blocks the breakdown of
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proteins, approved by the U.S. Food & Drug Administration in May of 2003 to treat myeloma,
with no toxicity issues.
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CHAPTER 3
Experimental
3.1 General Procedure
All chemicals were reagent grade from Acros Organics Incorporated and used as
purchased. The moisture sensitive reactions were performed under an inert atmosphere of dry
nitrogen with dried solvents. 4-hydroxybenzaldehyde was converted into 4-alkoxybenzaldehyde
via Williamson Ether synthesis. The Claisen-Schmidt condensation was then utilized to convert
4-alkozybenzaldehyde into both the methoxychalcones as well as the boronic acid chalcones.
Each compound prepared was then characterized by 1H and 13C NMR spectra were recorded on a
VANCE II at 400 and 100 MHz. The coupling constant (J) are reported in Hz. Melting point
ranges were ran on MEL TEMP and recorded in degree Celsius .
3.2 Synthesis of 4-alkoxybenzaldehydes (1a-8a)
4-Hydroxybexnzaldehyde (50 mmol, 6.106 g) and potassium carbonate, K2CO3 (50
mmol, 6.91 g) were added to 2-butanone (75 mL) in a 250 mL round bottom flask. The reaction
mixture was heated to 60-65 °C for 30 minutes, followed by the addition of 1-bromoalkane
(C3H7Br to C12H25Br, 50 mmol) was added drop wise and the reaction mixture was heated to
reflux for 18 hours. The solvent was evaporated under reduced pressure on a rotary evaporator,
then separated with diethyl ether (125 mL). Unreacted starting materials were washed with
distilled water and 10% sodium hydroxide, NaOH. Ether layer was dried over magnesium
sulfate, MgSO4, then evaporated and distilled to give 4-alkoxybenzaldehydes 1a-8a. All resulting
compounds were either pale yellow or yellow liquids, but some resulted in solids.
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Scheme 5. Williamson Ether synthesis of 4-alkoxybenzaldehyde.
3.2.1 4-(pentyloxy)benzaldehyde (1a). 4-hydroxybenzaldehyde (6.121 g, 50 mmol) and
1-bromopentane (7.592 g, 50 mmol) were reacted according to the general procedure. A pale
yellow liquid was obtained with a yield of 69% (6.627 g). 1H NMR (301 MHz, Chloroform-d) δ
9.86 (d, J = 3.1 Hz, 1H), 8.13 – 7.50 (m, 2H), 7.14 – 6.61 (m, 2H), 4.02 (t, J = 6.4 Hz, 2H), 1.81
(q, J = 7.5, 6.5 Hz, 2H), 1.69 – 1.16 (m, 4H), 1.13 – 0.64 (m, 3H).
3.2.2 4-(hexyloxy)benzaldehyde (2a). 4-hydroxybenzaldehyde (6.127 g, 50 mmol) and
1-bromohexane (8.294 g, 50 mmol) were reacted according to the general procedure. A yellow
liquid was collected with a yield of 68% (6.976 g). 1H NMR (301 MHz, Chloroform-d) δ 9.87
(d, J = 3.6 Hz, 1H), 8.17 – 7.57 (m, 2H), 7.19 – 6.61 (m, 2H), 4.03 (q, J = 6.5, 5.4 Hz, 2H), 1.79
(dd, J = 13.5, 7.0 Hz, 2H), 1.39 (d, J = 45.2 Hz, 9H), 1.16 – 0.71 (m, 4H).
3.2.3 4-(heptyloxy)benzaldehyde (3a). 4-hydroxybenzaldehyde (6.111 g, 50 mmol) and
1-bromoheptane (8.968 g, 50 mmol) were reacted according to the general procedure. A yellow
liquid/solid matter was obtained with a yield of 61% (6.791 g). 1H NMR (301 MHz,
Chloroform-d) δ 10.16 – 9.67 (m, 1H), 8.15 – 7.72 (m, 2H), 7.44 – 6.85 (m, 2H), 4.02 (dd, J =
7.5, 5.8 Hz, 2H), 1.80 (dq, J = 14.1, 6.9, 6.4 Hz, 2H), 1.56 – 1.06 (m, 11H), 1.06 – 0.75 (m, 3H).
3.2.4 4-(octyloxy)benzaldehyde (4a). 4-hydroxybenzaldehyde (6.104 g, 50 mmol) and 1bromooctane (9.716g, 50 mmol) were reacted according to the general procedure. An orange
liquid was observed with a yield of 30% (3.492 g). 1H NMR (301 MHz, Chloroform-d) δ 9.87 (s,
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1H), 7.82 (d, J = 7.9 Hz, 2H), 7.28 – 6.52 (m, 2H), 4.03 (t, J = 6.2 Hz, 2H), 3.39 (t, J = 6.6 Hz,
0H), 1.81 (h, J = 6.6 Hz, 2H), 1.69 – 1.08 (m, 15H), 1.08 – 0.57 (m, 5H).
3.2.5 4-(nonyloxy)benzaldehyde (5a). 4-hydroxybenzaldehyde (6.913 g, 50 mmol) and
1-bromononane (10.377 g, 50 mmol) were reacted according to the general procedure. A yellow
solid was gathered with a yield of 28% (3.528 g). 1H NMR (301 MHz, Chloroform-d) δ 9.86 (s,
1H), 7.81 (d, J = 8.5 Hz, 1H), 6.97 (d, J = 8.5 Hz, 2H), 4.02 (t, J = 6.6 Hz, 2H), 1.78 (q, J = 6.9
Hz, 2H), 1.58 – 1.13 (m, 8H), 0.87 (t, J = 6.5 Hz, 2H).
3.2.6 4-(decyloxy)benzaldehyde (6a). 4-hydroxybenzaldehyde (6.177 g, 50 mmol) and
1-bromodecane (11.079 g, 50 mmol) were reacted according to the general procedure. A yellow
solid/liquid matter was observed with a yield of 51% (6.707 g). 1H NMR (301 MHz,
Chloroform-d) δ 9.86 (d, J = 1.8 Hz, 1H), 8.06 – 7.66 (m, 1H), 7.17 – 6.58 (m, 2H), 4.28 – 3.57
(m, 2H), 1.80 (t, J = 7.1 Hz, 1H), 1.56 – 1.08 (m, 8H), 1.02 – 0.64 (m, 2H).
3.2.7 4-(undecyloxy)benzaldehyde (7a). 4- hydroxybenzaldehyde (6.176 g, 50 mmol)
and 1-bromoundecane (11.776 g, 50 mmol) were reacted according to the general procedure. A
yellow solid with a yield of 52% (7.250 g) was collected. 1H NMR (301 MHz, Chloroform-d) δ
9.87 (d, J = 3.1 Hz, 1H), 8.06 – 7.59 (m, 2H), 6.98 (d, J = 8.2 Hz, 2H), 4.46 – 3.72 (m, 2H), 2.16
– 1.73 (m, 1H), 1.73 – 1.04 (m, 11H), 1.08 – 0.41 (m, 3H).
3.2.8 4-(dodecyloxy)benzaldehyde (8a). 4-hydroxybenzaldehyde (6.109 g, 50 mmol)
and 1-bromododecane (12.482 g, 50 mmol) were reacted according to the general procedure. A
pale yellow solid was collected with a yield of 67% (9.781 g). 1H NMR (301 MHz, Chloroformd) δ 9.87 (d, J = 3.1 Hz, 1H), 8.06 – 7.59 (m, 2H), 6.98 (d, J = 8.2 Hz, 2H), 4.46 – 3.72 (m, 2H),
1.80 (p, J = 6.7 Hz, 1H), 1.73 – 1.04 (m, 11H), 1.08 – 0.41 (m, 3H).
3.3 Synthesis of 4-alkoxymethoxychalcones (1b-8b)
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In a 100 mL round bottom 4-methoxyacetophenone (equal molar equivalence) was
dissolved in ethanol (20 mL). 10% NaOH (5 equivalence) was added and the reaction mixture
was stirred for 30 minutes at room temperature. Then 4-alkoxybenzaldehyde 1a-8a (1.000 g) was
added to the reaction mixture that was further stirred for 18 hours until pale yellow precipitates
appeared. Crushed ice (35 mL) was added to the solid mass and the reaction was neutralized with
dilute HCl. The products 1b-8b was obtained as yellow solids, which were filtered and
recrystallized from ethanol.
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Scheme 6. Claisen-Schmidt condensation of 4-alkoxymethoxychalcone.
3.3.1 (E)-1-(4-methoxyphenyl)-3-(4-(pentyloxy)phenyl)prop-2-en-1-one (1b). 4methoxyacetophenone (1.009 g, 5.2 mmol) and 4-(pentyloxy)benzaldehyde (0.788 g, 5.2 mmol)
were reacted according to the general procedure. Yellow solids were obtained with a yield of
68% (1.146 g). m.p. 94-99 °C; 1H NMR (301 MHz, Chloroform-d) δ 8.04 (d, J = 8.2 Hz, 1H),
7.79 (d, J = 15.5 Hz, 0H), 7.60 (d, J = 8.4 Hz, 1H), 7.44 (d, J = 18.6 Hz, 1H), 6.96 (dd, J = 17.4,
8.2 Hz, 2H), 4.44 – 3.46 (m, 3H), 2.51 (d, J = 5.6 Hz, 0H), 1.81 (s, 2H), 1.46 (d, J = 14.8 Hz,
3H), 0.96 (q, J = 7.0, 6.1 Hz, 3H).
3.3.2 (E)-1-(4-(hexyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (2b). 4methoxyacetophenone (1.002 g, 4.85 mmol) and 4-(hexyloxy)benzaldehyde (0.731 g, 4.85
mmol) were reacted according to the general procedure. Pale yellow solids were collected with a
yield of 81% (1.334 g). m.p. 93-99 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.08 – 7.99 (m,
2H), 7.77 (d, J = 15.5 Hz, 1H), 7.64 – 7.55 (m, 2H), 7.50 – 7.46 (m, 1H), 7.42 (d, J = 15.6 Hz,

OR
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1H), 7.00 – 6.96 (m, 2H), 6.94 – 6.89 (m, 2H), 3.99 (q, J = 6.5 Hz, 3H), 3.93 – 3.82 (m, 3H),
1.88 – 1.69 (m, 3H), 1.46 (tdd, J = 9.5, 5.0, 2.9 Hz, 3H), 1.41 – 1.27 (m, 5H), 0.97 (d, J = 6.6 Hz,
2H), 0.91 (ddt, J = 7.3, 5.1, 2.1 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 200.33, 188.75, 163.21,
161.13, 143.90, 142.26, 131.39, 130.66, 130.07, 129.92, 127.55, 126.97, 124.30, 119.35, 114.87,
113.74, 68.16, 55.46, 49.84, 31.54, 29.12, 25.67, 25.66, 25.35, 22.72, 22.58, 14.01.
3.3.3 (E)- 3-(4-(heptyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (3b). 4methoxyacetophenone (0.686 g, 4.54 mmol) and 4-(heptyloxy)benzaldehyde (1.011 g, 4.54
mmol) were reacted according to the general procedure. Pale yellow solids were gathered with a
yield of 70% (1.116 g). m.p. 85-94 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.06 – 7.99 (m,
2H), 7.81 – 7.73 (m, 1H), 7.60 – 7.53 (m, 2H), 7.42 (d, J = 15.6 Hz, 1H), 7.00 – 6.94 (m, 2H),
6.94 – 6.88 (m, 2H), 4.07 – 3.93 (m, 3H), 3.87 (s, 3H), 1.91 – 1.70 (m, 4H), 1.44 (dddd, J = 9.2,
5.9, 4.5, 2.9 Hz, 3H), 1.39 – 1.22 (m, 9H), 0.92 – 0.81 (m, 4H).13C NMR (101 MHz, CDCl3) δ
188.52, 163.02, 160.94, 143.71, 131.18, 129.88, 129.73, 127.33, 119.13, 114.66, 113.55, 67.96,
55.25, 49.64, 31.56, 28.97, 28.84, 25.77, 25.15, 22.53, 22.40, 13.89.
3.3.4 (E)-1-(4-methoxyphenyl)-3-(4-(octyloxy)phenyl)prop-2-en-1-one (4b). 4methoxyacetophenone (0.672 g, 4.27 mmol) and 4-(octyloxy)benzaldehyde (1.006 g, 4.27 mmol)
were reacted according to the general procedure. Beige solids; yield 58% (0.914 g); m.p. 94-96
°C; 1H NMR (400 MHz, Chloroform-d) δ 8.08 – 7.99 (m, 1H), 7.77 (d, J = 15.5 Hz, 1H), 7.63 –
7.55 (m, 1H), 7.47 – 7.37 (m, 1H), 7.02 – 6.94 (m, 1H), 6.94 – 6.88 (m, 1H), 3.99 (t, J = 6.5 Hz,
1H), 3.88 (s, 2H), 1.89 – 1.69 (m, 1H), 1.53 – 1.40 (m, 1H), 1.40 – 1.19 (m, 5H), 0.94 – 0.80 (m,
2H). 13C NMR (101 MHz, cdcl3) δ 188.59, 163.05, 160.96, 143.74, 142.11, 131.22, 130.50,
129.91, 129.76, 127.38, 126.80, 124.13, 119.18, 114.69, 113.58, 68.01, 55.29, 49.67, 31.63,
29.16, 28.99, 25.83, 22.56, 13.93.
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3.3.5 (E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop-2-en-1-one (5b). 4methoxyacetophone (0.607 g, 4.03 mmol) and 4-(nonyloxy)benzaldehyde (1.000 g, 4.03 mmol)
were reacted according to the general procedure. Beige solid were collected with a yield of 68%
(1.048 g). m.p. 105-106°C; 1H NMR (400 MHz, Methanol-d4) δ 8.01 (d, J = 7.7 Hz, 1H), 7.79 –
7.71 (m, 1H), 7.70 – 7.65 (m, 1H), 7.60 (d, J = 9.6 Hz, 1H), 7.58 – 7.52 (m, 2H), 7.01 – 6.87 (m,
2H), 6.68 (d, J = 16.1 Hz, 1H), 3.99 (dt, J = 8.2, 6.4 Hz, 2H), 1.82 – 1.68 (m, 2H), 1.50 – 1.37
(m, 3H), 1.39 – 1.22 (m, 11H), 0.91 – 0.84 (m, 3H).13C NMR (101 MHz, CDCl3) δ 188.59,
163.04, 160.96, 143.75, 131.20, 130.50, 129.92, 127.35, 119.14, 114.68, 113.58, 68.00, 55.30,
31.70, 29.35, 29.21, 29.09, 28.99, 25.83, 22.50, 13.95.
3.3.6 (E)- 3-(4-(decyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (6b). 4methoxyacetophenone (0.575 g, 3.81 mmol) and 4-(decyloxy)benzaldehyde (1.060 g, 3.81
mmol) were reacted according to the general procedure. Beige solid were collected with a yield
of 91% (1.361 g). m.p. 82-97 °C; 1H NMR (400 MHz, Chloroform-d) δ 7.77 (d, J = 15.6 Hz,
1H), 7.62 – 7.55 (m, 2H), 7.50 – 7.46 (m, 1H), 7.42 (d, J = 15.6 Hz, 1H), 7.02 – 6.94 (m, 2H),
6.94 – 6.89 (m, 2H), 3.98 (q, J = 6.5 Hz, 3H), 3.88 (s, 3H), 2.50 (d, J = 7.0 Hz, 1H), 1.88 – 1.71
(m, 3H), 1.52 – 1.18 (m, 18H), 0.93 – 0.80 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 188.60,
163.04, 160.96, 143.76, 142.13, 131.20, 130.50, 129.92, 129.76, 127.36, 126.78, 124.11, 119.15,
114.69, 113.58, 68.00, 55.30, 49.67, 31.72, 29.20, 29.14, 28.99, 25.82, 25.19, 22.51, 13.95.
3.3.7 (E)-1-(4-methoxyphenyl)-3-(4-(undecyloxy)phenyl)prop-2-en-1-one (7b). 4methoxyacetophenone (0.549 g, 3.62 mmol) and 4-(undecyloxy)benzaldehyde (1.006 g, 3.62
mmol) were reacted according to the general procedure. White solid with a yield 76% (1.121 g)
were collected. m.p. 95-102 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.06 – 7.99 (m, 1H), 7.77
(d, J = 15.6 Hz, 0H), 7.63 – 7.54 (m, 1H), 7.42 (d, J = 15.6 Hz, 0H), 7.02 – 6.95 (m, 1H), 6.94 –
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6.89 (m, 1H), 3.98 (q, J = 6.6 Hz, 1H), 3.88 (s, 1H), 2.50 (d, J = 7.0 Hz, 1H), 1.87 – 1.68 (m,
1H), 1.53 – 1.09 (m, 10H), 0.92 – 0.78 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 188.76, 163.21,
161.13, 143.91, 142.28, 131.38, 130.67, 130.08, 129.92, 127.54, 126.96, 124.29, 119.34, 114.87,
113.75, 68.17, 55.46, 49.84, 31.90, 29.60, 29.32, 29.15, 25.99, 25.36, 22.68, 14.11.
3.3.8 (E)-3-(4-(dodecyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (8b). 4methoxyacetophenone (0.523 g, 3.44 mmol) and 4-(dodecyloxy)benzaldehyde (1.007 g, 3.44
mmol) were reacted according to the general procedure. White solids were collected with a yield
of 70% (1.017 g). m.p. 94-102 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.06 – 8.00 (m, 1H),
7.77 (d, J = 15.6 Hz, 1H), 7.61 – 7.55 (m, 1H), 7.42 (d, J = 15.6 Hz, 1H), 7.00 – 6.94 (m, 1H),
6.94 – 6.88 (m, 1H), 4.07 – 3.92 (m, 2H), 3.88 (s, 2H), 1.85 – 1.66 (m, 2H), 1.52 – 1.40 (m, 2H),
1.40 – 1.21 (m, 14H), 0.92 – 0.79 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 190.58, 188.54,
163.03, 160.95, 143.72, 142.08, 131.21, 130.48, 129.89, 129.74, 127.36, 124.11, 119.15, 114.68,
113.57, 67.99, 55.27, 49.66, 31.73, 29.47, 29.41, 29.19, 28.98, 28.86, 25.82, 25.17, 22.55, 13.94.
3.4 Synthesis of 4-alkoxyboronic acid chalcones (1c-8c)
In a 100 mL round bottom 4-acetylphenylboronic acid (equal molar equivalence) was
dissolved in ethanol (20 mL). 10% NaOH (5 equivalence) was added and the reaction mixture
was stirred for 30 minutes at room temperature. Then 4-alkoxybenzaldehyde 1a-8a (1.000 g) was
added to the reaction mixture that was further stirred for 18 hours until pale yellow precipitates
appeared. Crushed ice (35 mL) was added to the solid mass and the reaction was neutralized with
dilute HCl. The products 1c-8c was obtained as yellow solids, which were filtered and
recrystallized from ethanol.
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Scheme 7. Claisen-Schmidt condensation of 4-alkoxyboronic acid chalcones.
3.4.1 4-((E)-3-(4-(pentyloxy)phenyl)acryloyl)phenylboronic acid (1c). 4acetylphenylboronic acid (0.853 g, 5.20 mmol) and 4-(pentyloxy)benzaldehyde (1.016 g, 5.20
mmol) were reacted according to the general procedure.
3.4.2 4-((E)-3-(4-(hexyloxy)phenyl)acryloyl)phenylboronic acid (2c). 4acetylphenylboronic acid (0.797 g, 4.85 mmol) and 4-(hexyloxy)benzaldehyde (1.005 g, 4.85
mmol) were reacted according to the general procedure. Yellow solids with a yield 64% (1.46 g)
were collected. m.p. 184-195 °C; 1H NMR (400 MHz, Methanol-d4) δ 8.04 – 7.96 (m, 1H), 7.90
(d, J = 7.7 Hz, 0H), 7.75 (d, J = 15.6 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.60 (d, J = 5.6 Hz, 0H), 7.57
– 7.52 (m, 1H), 6.99 – 6.89 (m, 1H), 6.69 (d, J = 16.1 Hz, 0H), 3.99 (q, J = 6.6 Hz, 1H), 1.76
(dtt, J = 7.9, 6.4, 5.2 Hz, 2H), 1.54 – 1.42 (m, 2H), 1.42 – 1.27 (m, 3H).
3.4.3 4- ((E)-3-(4-heptyloxy)phenyl)acryloyl)phenyloboronic acid (3c). 4acetylphenylboronic acid (0.755g, 4.54 mmol) and 4-(heptyloxy)benzaldehyde (1.007 g, 4.54
mmol) were reacted according to the general procedure. Yellow solids with a yield of 88%
(1.460 g) was collected. m.p. 121-186 °C; 1H NMR (400 MHz, Methanol-d4) δ 7.93 (d, J = 7.6
Hz, 1H), 7.84 (d, J = 8.8 Hz, 0H), 7.73 (d, J = 15.5 Hz, 1H), 7.70 – 7.65 (m, 1H), 7.65 (s, 0H),
7.60 (d, J = 3.5 Hz, 0H), 7.59 – 7.54 (m, 1H), 4.06 (t, J = 6.4 Hz, 0H), 4.00 (dt, J = 7.7, 6.4 Hz,
2H), 3.89 (s, 0H), 2.25 – 2.03 (m, 1H), 1.77 (dddd, J = 12.7, 8.4, 6.5, 3.3 Hz, 3H), 1.56 – 1.41
(m, 2H), 1.41 – 1.21 (m, 6H), 1.03 – 0.75 (m, 6H).13C NMR (101 MHz, CD3OD) δ 201.77,
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191.41, 161.42, 143.31, 133.20, 131.70, 130.10, 129.92, 127.43, 126.84, 126.52, 123.55, 119.38,
114.55, 31.57, 28.91, 28.79, 25.69, 22.27, 21.56, 13.02.
3.4.4 4-((E)-3-(4-(octyloxy)phenyl)acryloyl)phenylboronic acid (4c). 4acetylphenylboronic acid (0.710 g, 4.27 mmol) and 4-(octyloxy)benzaldehyde (0.998 g, 4.27
mmol) were reacted according to the general procedure. Beige solid; yield 58% (0.938 g)
3.4.5 4-(E))-3-(4-(nonyloxy)phenyl)acryloyl)phenylboronic acid (5c). 4acetylphenylboronic acid (0.667 g, 4.03 mmol) and 4-(nonyloxy)benzaldehyde (1.001 g, 4.03
mmol) were reacted according to the general procedure. Pale yellow solids were collected with a
yield of 67% (1.069 g). m.p. 103-164 °C; 1H NMR (400 MHz, Methanol-d4) δ 8.01 (d, J = 7.7
Hz, 1H), 7.79 – 7.71 (m, 1H), 7.70 – 7.65 (m, 1H), 7.60 (d, J = 9.6 Hz, 1H), 7.58 – 7.52 (m, 2H),
7.01 – 6.87 (m, 2H), 6.68 (d, J = 16.1 Hz, 1H), 3.99 (dt, J = 8.2, 6.4 Hz, 2H), 1.82 – 1.68 (m,
2H), 1.50 – 1.37 (m, 3H), 1.39 – 1.22 (m, 11H), 0.91 – 0.84 (m, 3H). 13C NMR (101 MHz,
CD3OD) δ 203.63, 163.49, 163.31, 146.99, 145.16, 133.21, 132.13, 131.77, 129.10, 128.89,
128.71, 125.41, 116.44, 116.39, 69.61, 31.12, 30.95, 30.85, 30.73, 27.57, 27.04, 24.17, 23.40,
14.88.
3.4.6 4-((E)-3-(4-decyloxy)phenyl)acryloyl)phenylboronic acid (6c). 4acetylphenylboronic acid (0.629 g, 3.81 mmol) and 4-(decyloxy)benzaldehyde (1.019 g, 3.81
mmol) were reacted according to the general procedure. Yellow solids were collected with a
yield of 84% (1.303 g). m.p. 109-163 °C.
3.4.7 4-((E)-3-(4-undecyloxy)phenyl)acryloyl)phenylboronic acid (7c). 4acetylphenylboronic acid (0.599 g, 3.62 mmol) and 4-(undecyloxy)benzaldehyde (1.018 g, 3.62
mmol) were reacted according to the general procedure. Yellow solid were collected with a yield
of 82% (1.247 g). m.p. 65-143 °C; 1H NMR (400 MHz, Methanol-d4) δ 8.00 (s, 1H), 7.84 (d, J =
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8.8 Hz, 1H), 7.76 (d, J = 15.5 Hz, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.59 –
7.52 (m, 2H), 7.00 – 6.88 (m, 3H), 6.70 (d, J = 16.1 Hz, 1H), 4.06 (s, 0H), 4.02 – 3.92 (m, 3H),
2.55 (d, J = 7.0 Hz, 2H), 2.27 – 2.01 (m, 2H), 1.85 – 1.65 (m, 4H), 1.53 – 1.18 (m, 24H), 0.96 (d,
J = 6.7 Hz, 4H), 0.92 – 0.82 (m, 4H).
3.4.8 4-((E)-3-(4-dodecyloxy)phenyl)acryloyl)phenylboronic acid (8c). 4acetylphenylboronic acid (0.564 g, 3.44 mmol) and 4-(dodecyloxy)benzaldehyde (1.012 g, 3.44
mmol) were reacted according to the general procedure. Pale yellow solids were gathered with a
yield of 75% (1.121 g).
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CHAPTER 4
Results and Discussion
4.1 Results and Discussion of Ether Synthesis
4.1.1 Yields of 4-alkoxybenzaldehydes. Synthetic yields including cLogP values
calculated from the 4-alkoxybenzaldehydes.
Table 1
Yields for 4-alkoxybenzaldehydes
S.No.

Product

cLogP

Yield
(%)

3.89

69

4.42

68

4.95

61

5.48

30

6.01

28

6.54

51

7.07

52

7.60

67

O
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O
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O
O
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O

O
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H
O
O
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H
O

O

6a

H
O
O

7a

H
O
O

8a

H
O

4.1.2 Discussion of solubility. The partition coefficient (Log P) is a measurement of a
compound’s solubility in a hydrophobic and hydrophilic solvent, usually octanol ant water. This
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value establishes a compound’s hydrophilicity and gives an insight to how a drug will be
metabolized in the body. High Log P values indicate that a compound is hydrophobic “water
fearing” and is more likely to absorb/permeate through the lipid bilayers. A low score for the
Log P value indicates that the drug is hydrophilic “water loving” and is more favored being that
the drug will metabolize through the blood serum. Within the pharmaceutical industry an
acceptable cLog P values is anything below a 5.0.
In regards to the solubility of the benzaldehydes, the solubility is completely dependent
on the ether chain attached to the ring. Before the ether chain was added onto 4hydroxybenzaldehye, its cLogP value was 1.44, making it a hydrophilic compound. As the chain
increased with carbons the value of cLogP increased. For that reason we can assume the
additional carbons make the compounds more hydrophobic.
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Figure 4. 1H NMR of 4-(nonyloxy)benzaldehyde
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4.1.3 Discussion of 1H NMR. The hydrocarbons on the ether chain, protons E-H, would
have a chemical shift found between 0-3 ppm. Proton E is a doublet at 3.41 ppm, protons F
shows a doublet of triplets at 1.83, proton G is a multiplet at 1.33 and proton H is a multiplet at
0.88 ppm. The hydrogen closest to the oxygen atom, proton D, had a chemical shift more
downfield at 4.03 ppm resulting in a triplet because of the deshielding from its neighboring
oxygen atom. Moving down the spectra towards the aromatic ring, the hydrogen on the benzene
ring protons B shows a doublet at 7.82 ppm and proton C is a multiplet at 6.99 ppm. The
aldehydic hydrogen, proton A, had the highest frequency at 9.87 ppm as a doublet because of the
strong dipole moment from the carbonyl.
4.2 Results and Discussion of 4-alkoxymethoxychalcone Synthesis
4.2.1 Yields of 4-alkoxymethoxychalcones. Synthetic yields including cLogP values
calculated from the 4-alkoxymethoxychalcones. Refer to Figure 2 for numbering sequence.
Table 2
Yields for 4-alkxoymethoxychalcones
B-ring
S.No.

4’-

A-ring

Yield
cLogP
(%)

Product

4O

1b

OCH3

C5H11
H3C

O

68

5.13

81

5.59

70

6.05

58

6.52

O
O
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OCH3

C6H13
H3C

O

O

O

3b

OCH3

C7H15
H3C

O

O
O
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OCH3

C8H17
H3C

O

O
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5b

OCH3

C9H19
H3C

O

68

6.98

91

7.45

76

7.91

70

8.37
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O
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OCH3
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O

O
O
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OCH3

C11H23
H3C

O

O
O
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OCH3

C12H25
H3C

O

O

4.2.2 Discussion of solubility. In regards to the solubility of the methoxychalcones, it is
assumed that the longer the ether chain the more nonpolar the compound is than the compounds
with the shorter chains. Confirming this statement is the cLogP value from Table 2. The
solubility value, when compared to its respected benzaldehyde starting material shows an
increase in cLlogP value. This indicates that these compounds are more likely to metabolize
through the lipid bilayers and would not be considered a target drug due to its high Log P values.
4.2.3 Discussion of 1H and 13C NMR. To confirm that the methoxychalcones were
synthesized we ran both a 1H NMR as well as a 13C NMR to compare them to their
corresponding benzaldehyde starting material (compounds 1a-8a). Figure 5 is the full spectrum
of the proton NMR for the nonane methoxychalcone. Figure 6 the highlights the aliphatic region
of the compound while Figure 7 highlights the aromatic region. This compound was ran in
deuterated chloroform (CDCl3) and the solvent peaks appear at 7.25 ppm. Within the aliphatic
proton G, the methoxy proton is a triplet with a chemical shift at 4.0 ppm. Proton H is the
methoxy proton attached to ring A is a singlet with a chemical shift at 3.9 ppm. Both the
methoxy protons are slightly downfield than that of the methyl protons because of the
deshielding affect oxygen has on the nucleus. In the ether chain are multiplets consisting of
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protons I, K, J and L. Proton I is a CH2 group at 1.80 ppm, proton K are CH2 groups that are not
equivalent but will show the same chemical shifts at 1.29 ppm. Proton J is another CH2 group at
1.45 and proton L is the last peak at 0.9.
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Figure 5. 1H NMR of (E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop-2-en-1-one.

Figure 6. 1H NMR aliphatic region of (E)-1-(4-methoxyphenyl)-3-(4-(nonlyoxy)phenyl)prop-2en-1-one.
In the aromatic region there are a series of doublets. Both benzene rings have two sets of
doublets that are difficult to label each protons chemical shift, but the vinyilic protons have
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doublets at 7.78 ppm (proton B) and 7.43 ppm (proton D). Normally vinyilic protons appear
between 4.6-5.7 ppm. To differentiate between the peaks that coupled in the aromatic region, a
two-dimensional nuclear resonance spectroscopy (2D NMR) was perform, specifically a
correlation spectroscopy (COSY) (Figure 8). Protons A and C are located on benzene ring A,
proton C is a doublet at 7.59 ppm and proton A is another doublet at 8.03 ppm. On the benzene
ring B are protons E and F, proton E is a doublet at 6.98 ppm and F is another doublet at 6.92
ppm.

Figure 7. 1H NMR aromatic region of (E)-1-(4-methoxyphenyl)-3-(4-(nonlyoxy)phenyl)prop-2en-1-one.
The 13C NMR allowed us to see how the chemical backbone was arranged, and what
functional groups are represented. The different peaks represent the varying environments of the
carbons. Figure 9 is the representative 13C NMR of the nonane methoxychalcone. It has total of
twenty five carbons in the chemical formula.
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Figure 8. 2D NMR COSY of (E)
(E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop
(nonyloxy)phenyl)prop-2-en-1-one.
Within the structure should be eighteen different carbon environments which should be
indicated by eighteen peaks. Starting with the alkane chain tthere are seven different chemical
environments. There are two methoxy carbonss that are slightly down field around 55.2 ppm and
68.2 ppm. The very last peak is the CH3 group at, the end
d of the chain in which shows up at 13
ppm. Three of the carbons within the chain have the same environment and show up around 29.3
ppm. The four carbons on the chain appear more downfield between 35
35-0 ppm. The alkene
carbons have two different environment
environments. The α carbon shows up around 126.9 ppm and the β
carbon appears at 143.5 ppm. The ccarbonyl is showcased down field around 188.3 ppm. The
aromatic rings will have a representation of four peaks because there are two sets of carbons that
have the same environment. This is true for bot
both ring systems in the compound.
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Figure 9. 13C NMR of (E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop-2-en-1-one.

4.3 Results and Discussions of 4-alkoxyboronic acid chalcone Synthesis
4.3.1 Yields of 4-alkoxyboronic acid chalcones. Synthetic yields including cLogP
values calculated from the 4-alkoxyboronic acid chalcones. Refer to Figure 2 for numbering
sequence
Table 3
Yields for 4-alkoxyboronic acid chalcones
B-ring
S.No.

4’-

A-ring
Product

4-
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cLogP
(%)
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4.3.2 Discussion of solubility. The solubility of the boronic acid chalcones follows the
trend with that of the others, as the chain increases in carbons the solubility increases. However
because of the boronic acid group on the other side of the compound the cLogP value
significantly dropped when compared to the methoxychalcones. This validates that by adding the
boronic acid functional group, the compounds become more soluble allowing it to have more
bioavailability. These compounds would be promising in the pharmaceutical industry due to its
low cLogP values indicating that they would metabolize through the blood serum.
4.3.3 Discussion of 1H and 13C NMR. The boronic acid chalcones were all ran in
deuterated methanol which has two peaks with chemical shifts of 4.8 ppm and 3.3 ppm. Similar
to the methoxy chalcones’ proton NMRs, Figure 10 showcases the full proton NMR, Figure 11 is
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the aliphatic region, and Figure 12 is the aromatic region. The chemical shifts are somewhat
similar to that of the methoxy chalcone in the aliphatic region with the exception of only
expecting one methoxy proton with a chemical shift around 4.0 ppm being that the boronic acid
chalcones have hydroxyl protons attached to its second ring instead of an extra methoxy group.
The same follows true for the aromatic region, both the vinylic protons and aromatic protons
have similar chemical shifts with exception of now having an extra peak that appears at 8.01
ppm representing the hydroxyl protons on the boron. Literature confirms that when boronic acid
is attached to a benzene ring, there is an expected chemical shift of 7.25-8.29 ppm (Bruns,
Sinnwell, & Voss, 2003).
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Figure 10. 1H NMR of 4-((E)-3-(4-(nonyloxy)phenyl)acryloyl)phenylboronic acid.
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Figure 11. 1H NMR aliphatic region of 4-((E)-3-(4-(nonyloxy)phenyl)acryloyl)phenylboronic
acid.

Figure 12. 1H NMR aromatic region of 4-((E)-3-(4-(nonyloxy)phenyl)acryloyl)phenylboronic
acid.
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Figure 13 is the representative 13C NMR of the nonane boronic acid chalcone.Peaks are
not as pronounced due to the solubility of the compound in the solvent. Again similar to that of
the methoxy chalcone we expect to see twenty five peaks for each of the carbons in the
compound, but eighteen different environments. The only difference is the slight down field shift
of the peaks that might be due to the boron. The biggest difference between the 13C NMR of the
methoxy and boronic acid chalcones is the carbonyl peak. In the methoxy spectrum the carbonyl
peak appears at 188.59 ppm but now in the boronic acid spectrum has a down field shift at
203.63 ppm. The presence of only one methoxy carbon instead of two signifies that there is
another difference between both the methoxy and boronic acid spectrums.

Figure 13. 13C NMR of ((E)-3-(4-(nonyloxy)phenyl)arcyloyl)phenylboronic acid
By comparing the NMR data from both the 1H NMR and 13C NMR of each chalcone
confirms t that there is a difference between the methoxychalcones and the boronic acid
chalcones. This difference can be made by the aliphatic regions of the 1H NMR and by different
carbonyl shifts in the 13C NMR.
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CHAPTER 5
Conclusion and Future Research
We have reported an attempt to synthesize twenty four chalcone derivatives. To the best
of our knowledge, thirteen of our chalcone derivatives have never being reported, this
investigation namely, five methoxy chalcones (4b-8b) and eight boronic acid chalcones (1c-8c).
The benzaldehyde compounds had much success with the Williamson Ether synthesis. An extra
step was added to ensure that the compounds were pure; the distillation via Kugelrohr. The
benzaldehydes that were synthesized are commercially available, but do not have any reported
melting point from their respected companies.
Out of the three reactions, the boronic acid chalcones took the most effort to recover. The
degree of difficulty came about when it came time to recrystallize the compounds. This was
partially due to the solubility of the compound and because of that three of the compounds were
not recovered. Another issue we encountered when synthesizing both sets of chalcones was
having starting material in the products. Evidence of the starting material, mainly benzaldehye,
showed up in the NMR spectra and could be the reason to why recrystallizing the compound had
a degree of difficulty. To deal with this issue an excess of acetophenone could be used instead of
equal molar quantity.
Once we recovered the three boronic acid chalcones lost in recrystallization, (1c, 4c and
8c) we want to add on with the discovery and add the butane and propane boronic acid chalcones
to the library, neither of which have been reported. The next step for both sets of chalcones is to
send them to the National Institute of Health Developmental Therapeutics Program to be
screened on cancer cell lines. This step will help with the development of a structure-activity
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relationship and to see if boronic acid will indeed have more biological availability than that of a
methoxy group as well as see if the ether chain has any affect on cancer.
During this research, we also encountered a crystal form of a chalcone that we
attempted to synthesize in the past (Figure 14). This too gives great insight to the characteristics
of chalcones. In the future we have hopes to further study this crystal and attempt to form
crystals with the other chalcones.

O

O
(E)-3-(4-(heptyloxy)phenyl)-1-phenylprop-2-en-1-one

Figure 14. Chalcone crystal structures.
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Appendix A
1

H NMR

4-(pentyloxy)benzaldehyde (1a)

4-(hexyloxy)benzaldehyde (2a)
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4-(heptyloxy)benzaldehyde (3a)

4-(octyloxy)benzaldehyde (4a)

50
4-(nonyloxy)benzaldehyde (5a)

4-(decyloxy)benzaldehyde (6a)
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4-(undecyloxy)benzaldehyde (7a)

4-(dodecyloxy)benzaldehyde (8a)

52
(E)-1-(4-methoxyphenyl)-3-(4-(pentyloxy)phenyl)prop-2-en-1-one (1b)

(E)-1-(4-(hexyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (2b)
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(E)- 3-(4-(heptyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (3b)

(E)-1-(4-methoxyphenyl)-3-(4-(octyloxy)phenyl)prop-2-en-1-one (4b)
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(E)- 3-(4-(decyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (6b)

(E)-1-(4-methoxyphenyl)-3-(4-(undecyloxy)phenyl)prop-2-en-1-one (7b)
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(E)-3-(4-(dodecyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (8b)

4-((E)-3-(4-(hexyloxy)phenyl)acryloyl)phenylboronic acid (2c)

56
4-((E)-3-(4-heptyloxy)phenyl)acryloyl)phenyloboronic acid (3c)

4-((E)-3-(4-undecyloxy)phenyl)acryloyl)phenylboronic acid (7c)
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13

C NMR

(E)-1-(4-(hexyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (2b )

(E)- 3-(4-(heptyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (3b)
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(E)-1-(4-methoxyphenyl)-3-(4-(octyloxy)phenyl)prop-2-en-1-one (4b)

(E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop-2-en-1-one (5b)
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(E)- 3-(4-(decyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (6b)

(E)-1-(4-methoxyphenyl)-3-(4-(undecyloxy)phenyl)prop-2-en-1-one (7b)
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(E)-3-(4-(dodecyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (8b)

4-((E)-3-(4-(hexyloxy)phenyl)acryloyl)phenylboronic acid (2c)
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4-((E)-3-(4-heptyloxy)phenyl)acryloyl)phenyloboronic acid (3c)

4-((E)-3-(4-undecyloxy)phenyl)acryloyl)phenylboronic acid (7c)
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Appendix C
Chalcone Crystal Tables
Table 1: Data collection details for Franks2.
dx/
Width/
Time
Voltage/ Current/ Tem/
2θ/° ω/° φ/° χ/°
Frame
λ/Å
°
/s
kV
mA
K
mm
44.
340.0
35.0
0.70
200.0
Omega
20.0
0.00
0.50
360
10.00
50
1.0
765
0
2
973
0
0
44.
0.70
200.0
340.0 120.0 35.0
Omega
20.0
0.50
360
10.00
50
1.0
765
973
0
0
0
2
0
44.
0.70
200.0
340.0 240.0 35.0
50
1.0
Omega
20.0
0.50
360
10.00
765
0
0
2
973
0
0
A total of 1080 frames were collected. The total exposure time was 3.00 hours. The integration
of the data using a triclinic unit cell yielded a total of 8223 reflections to a maximum θ angle of
25.05° (0.84 Å resolution), of which 3228 were independent (average redundancy 2.547,
completeness = 98.0%, Rint = 5.44%, Rsig = 8.92%) and 2386 (73.92%) were greater than
2σ(F2).The final cell constants of a = 5.6069(9) Å, b = 7.7822(13) Å, c = 22.864(4) Å, α =
81.101(5)°, β = 85.571(5)°, γ = 69.879(4)°, volume = 925.2(3) Å3, are based upon the refinement
of the XYZ-centroids of 2559 reflections above 20 σ(I) with 5.404° < 2θ < 49.74°.Data were
corrected for absorption effects using the multi-scan method (SADABS). The ratio of minimum
to maximum apparent transmission was 0.627. The calculated minimum and maximum
transmission coefficients (based on crystal size) are 0.9648 and 0.9885.
Axis

The structure was solved and refined using the Bruker SHELXTL Software Package, using the
space group P -1, with Z = 2 for the formula unit, C22H26O2.The final anisotropic full-matrix
least-squares refinement on F2 with 228 variables converged at R1 = 6.51%, for the observed
data and wR2 = 20.77% for all data. The goodness-of-fit was 1.190. The largest peak in the final
difference electron density synthesis was 0.552 e-/Å3 and the largest hole was -0.276 e-/Å3 with
an RMS deviation of 0.116 e-/Å3. On the basis of the final model, the calculated density was
1.157 g/cm3 and F(000), 348 e-.
Table 2. Sample and crystal data for Franks2.
Identification code
Chemical formula
Formula weight
Temperature
Wavelength
Crystal size
Crystal habit

Franks2
C22H26O2
322.43
200(2) K
0.71073 Å
0.16 x 0.26 x 0.50 mm
colorless plate
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Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)

triclinic
P -1
a = 5.6069(9) Å
b = 7.7822(13) Å
c = 22.864(4) Å
925.2(3) Å3
2
1.157 Mg/cm3
0.072 mm-1
348

α = 81.101(5)°
β = 85.571(5)°
γ = 69.879(4)°

Table 3. Data collection and structure refinement for Franks2.
Bruker Smart X2S Diffractometer
Diffractometer
microfocus sealed tube, Mo Kα
Radiation source
Theta range for data
0.90 to 25.05°
collection
-6<=h<=6, -9<=k<=9, -27<=l<=27
Index ranges
8223
Reflections collected
3228 [R(int) = 0.0544]
Independent reflections
Coverage of independent
98.0%
reflections
multi-scan
Absorption correction
Max. and min.
0.9885 and 0.9648
transmission
Structure solution
direct methods
technique
Structure solution program SHELXS-97 (Sheldrick, 2008)
Full-matrix least-squares on F2
Refinement method
SHELXL-97 (Sheldrick, 2008)
Refinement program
Σ w(Fo2 - Fc2)2
Function minimized
Data / restraints /
3228 / 0 / 228
parameters
1.190
Goodness-of-fit on F2
2386 data;
R1 = 0.0651, wR2 =
Final R indices
I>2σ(I)
0.1697
R1 = 0.0854, wR2 =
all data
0.2077
2
2
w=1/[σ (Fo )+(0.0979P)2+0.0000P]
Weighting scheme
where P=(Fo2+2Fc2)/3
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0.0570(120)
Extinction coefficient
Largest diff. peak and hole 0.552 and -0.276 eÅ-3
R.M.S. deviation from
0.116 eÅ-3
mean

Table 4. Atomic coordinates and equivalent
isotropic atomic displacement parameters
(Å2) for Franks2.
U(eq) is defined as one third of the trace of the
orthogonalized Uij tensor.

x/a
y/b
z/c
U(eq)
C11 0.6979(3) 0.2351(2) 0.61650(8) 0.0373(5)
C12 0.8440(4) 0.2089(2) 0.66932(9) 0.0401(5)
C10 0.8257(3) 0.1746(2) 0.56517(8) 0.0421(5)
O1 0.2981(2) 0.31056(16) 0.46311(5) 0.0443(4)
O2 0.1747(3) 0.1737(2) 0.75749(6) 0.0669(5)
C1 0.2058(5) 0.2485(3) 0.08678(10) 0.0809(11)
C2 0.0852(4) 0.2923(3) 0.14694(9) 0.0610(6)
C3 0.2731(4) 0.2277(2) 0.19622(8) 0.0480(5)
C4 0.1557(4) 0.2757(2) 0.25614(8) 0.0462(5)
C5 0.3482(3) 0.2293(2) 0.30457(8) 0.0437(5)
C6 0.2296(3) 0.2862(2) 0.36364(8) 0.0424(5)
C7 0.4238(4) 0.2392(2) 0.41054(8) 0.0412(5)
C8 0.4414(3) 0.2829(2) 0.51157(8) 0.0360(5)
C9 0.7019(4) 0.1964(2) 0.51296(8) 0.0425(5)
C13 0.7633(4) 0.2386(2) 0.72417(9) 0.0406(5)
C14 0.9482(4) 0.2096(2) 0.77038(9) 0.0440(5)
C15 0.8612(4) 0.2268(2) 0.83310(8) 0.0417(5)
C16 0.6110(4) 0.3095(3) 0.85062(9) 0.0494(6)
C17 0.5449(4) 0.3288(3) 0.90944(9) 0.0585(6)
C18 0.7295(5) 0.2628(3) 0.95184(10) 0.0613(6)
C19 0.3094(3) 0.3496(2) 0.56215(8) 0.0401(5)
C20 0.4342(3) 0.3248(2) 0.61376(8) 0.0390(5)
C21 0.9803(4) 0.1774(3) 0.93508(9) 0.0593(6)
C22 0.0452(4) 0.1600(3) 0.87671(9) 0.0502(6)

Table 5. Bond lengths (Å) for Franks2.
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C11-C10
C11-C12
C12-H13
C10-H10
O1-C7
C1-C2
C1-H1B
C2-C3
C2-H2B
C3-H3A
C4-C5
C4-H4B
C5-H5A
C6-C7
C6-H6B
C7-H7B
C8-C19
C13-C14
C14-C15
C15-C22
C16-H16
C17-H17
C18-H18
C19-H19
C21-C22
C22-H22

1.386(3)
1.460(2)
0.934(19)
0.949
1.434(2)
1.519(3)
0.98
1.508(2)
0.99
0.99
1.521(2)
0.99
0.99
1.502(2)
0.99
0.99
1.394(2)
1.475(2)
1.490(3)
1.399(2)
0.95
0.95
0.95
0.95
1.371(3)
0.95

C11-C20
C12-C13
C10-C9
O1-C8
O2-C14
C1-H1A
C1-H1C
C2-H2A
C3-C4
C3-H3B
C4-H4A
C5-C6
C5-H5B
C6-H6A
C7-H7A
C8-C9
C9-H9
C13-H12
C15-C16
C16-C17
C17-C18
C18-C21
C19-C20
C20-H20
C21-H21

1.403(3)
1.327(3)
1.386(2)
1.365(2)
1.226(2)
0.98
0.98
0.99
1.516(3)
0.99
0.99
1.518(2)
0.99
0.99
0.99
1.383(3)
0.95
0.95(2)
1.384(3)
1.384(3)
1.382(3)
1.385(3)
1.372(2)
0.95
0.95

Table 6. Bond angles (°) for Franks2.
C10-C11-C20 117.38(16) C10-C11-C12
C20-C11-C12 123.75(17) C13-C12-C11
C13-C12-H13 117.3(11) C11-C12-H13
C9-C10-C11 122.48(17) C9-C10-H10
C11-C10-H10 118.7
C8-O1-C7
C2-C1-H1A
109.5
C2-C1-H1B
H1A-C1-H1B 109.5
C2-C1-H1C
H1A-C1-H1C 109.5
H1B-C1-H1C
C3-C2-C1
113.5(2)
C3-C2-H2A

118.82(17)
129.55(19)
113.1(11)
118.8
118.07(14)
109.5
109.5
109.5
108.9
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C1-C2-H2A
C1-C2-H2B
C2-C3-C4
C4-C3-H3A
C4-C3-H3B
C3-C4-C5
C5-C4-H4A
C5-C4-H4B
C6-C5-C4
C4-C5-H5A
C4-C5-H5B
C7-C6-C5
C5-C6-H6A
C5-C6-H6B
O1-C7-C6
C6-C7-H7A
C6-C7-H7B
O1-C8-C9
C9-C8-C19
C8-C9-H9
C12-C13-C14
C14-C13-H12
O2-C14-C15
C16-C15-C22
C22-C15-C14
C15-C16-H16
C18-C17-C16
C16-C17-H17
C17-C18-H18
C20-C19-C8
C8-C19-H19
C19-C20-H20
C22-C21-C18
C18-C21-H21
C21-C22-H22

108.9
108.9
113.85(18)
108.8
108.8
114.00(17)
108.8
108.8
113.52(16)
108.9
108.9
112.37(15)
109.1
109.1
108.46(14)
110.0
110.0
124.51(17)
119.54(16)
120.5
119.98(18)
118.2(11)
119.19(16)
118.12(18)
117.85(18)
119.5
120.0(2)
120.0
120.2
120.69(17)
119.7
119.6
120.18(19)
119.9
119.5

C3-C2-H2B
H2A-C2-H2B
C2-C3-H3A
C2-C3-H3B
H3A-C3-H3B
C3-C4-H4A
C3-C4-H4B
H4A-C4-H4B
C6-C5-H5A
C6-C5-H5B
H5A-C5-H5B
C7-C6-H6A
C7-C6-H6B
H6A-C6-H6B
O1-C7-H7A
O1-C7-H7B
H7A-C7-H7B
O1-C8-C19
C8-C9-C10
C10-C9-H9
C12-C13-H12
O2-C14-C13
C13-C14-C15
C16-C15-C14
C15-C16-C17
C17-C16-H16
C18-C17-H17
C17-C18-C21
C21-C18-H18
C20-C19-H19
C19-C20-C11
C11-C20-H20
C22-C21-H21
C21-C22-C15
C15-C22-H22

108.9
107.7
108.8
108.8
107.7
108.8
108.8
107.6
108.9
108.9
107.7
109.1
109.1
107.9
110.0
110.0
108.4
115.95(15)
119.06(18)
120.5
121.8(11)
120.41(18)
120.39(17)
124.01(17)
120.99(18)
119.5
120.0
119.6(2)
120.2
119.7
120.81(17)
119.6
119.9
121.1(2)
119.5

Table 7. Anisotropic atomic displacement parameters (Å2) for
Franks2.
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The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2
U11 + ... + 2 h k a* b* U12 ]

U11
U22
U33
U23
U13
U12
C11 0.0381(11) 0.0313(8) 0.0435(11) -0.0044(7) -0.0017(9) -0.0132(8)
C12 0.0350(12) 0.0382(9) 0.0466(12) -0.0038(8) -0.0019(9) -0.0124(8)
C10 0.0333(11) 0.0415(9) 0.0507(12) -0.0119(8) -0.0004(9) -0.0094(8)
O1 0.0407(8) 0.0490(7) 0.0374(8) -0.0082(6) -0.0044(6) -0.0059(6)
O2 0.0403(10) 0.1027(12) 0.0556(10) -0.0106(8) -0.0044(7) -0.0207(8)
C1 0.120(3) 0.0757(16) 0.0502(15)
0.0115(11) 0.0160(14) 0.0329(16)
C2 0.0783(17) 0.0532(11) 0.0493(13)
0.0081(10) 0.0188(12) 0.0151(11)
C3 0.0554(13) 0.0416(10) 0.0454(12) -0.0049(8)
-0.0138(9)
0.0060(10)
C4 0.0508(13) 0.0389(9) 0.0455(12) -0.0044(8)
-0.0098(9)
0.0085(10)
C5 0.0453(12) 0.0409(9) 0.0430(12) -0.0065(8) -0.0041(9) -0.0113(9)
C6 0.0471(13) 0.0382(9) 0.0398(11) -0.0050(8) -0.0019(9) -0.0115(9)
C7 0.0439(12) 0.0382(9) 0.0398(11) -0.0096(8) 0.0034(9) -0.0107(8)
C8 0.0401(11) 0.0301(8) 0.0372(10) -0.0039(7) -0.0022(8) -0.0111(8)
C9 0.0402(12) 0.0430(9) 0.0439(11) -0.0131(8) 0.0021(9) -0.0113(8)
C13 0.0365(13) 0.0422(10) 0.0437(12) -0.0013(8) -0.0057(9) -0.0149(9)
C14 0.0384(12) 0.0448(10) 0.0488(12) -0.0009(8) -0.0066(9) -0.0151(9)
C15 0.0467(13) 0.0402(9) 0.0432(11) -0.0018(8) -0.0080(9) -0.0212(9)
C16 0.0419(13) 0.0563(11) 0.0505(13) -0.0072(9)
-0.0160(9)
0.0068(10)
C17 0.0539(14) 0.0694(13) 0.0537(13)
0.0014(10)
0.0145(10)
0.0207(11)
C18 0.0736(17) 0.0729(14) 0.0446(12)
0.0104(10) 0.0018(11) 0.0328(13)
C19 0.0346(11) 0.0402(9) 0.0420(11) -0.0050(8) -0.0004(8) -0.0085(8)
C20 0.0378(11) 0.0401(9) 0.0369(10) -0.0046(7) 0.0025(8) -0.0115(8)
C21 0.0655(16) 0.0686(13) 0.0475(13) 0.0002(10)
0.0155(11) 0.0279(12)
C22 0.0470(13) 0.0539(11) 0.0502(13) -0.0005(9)
0.0103(10) 0.0185(10)

